◆ 会议时间：2022年5月12-14日
◆ 会议地点：日本 横滨

◆ 会议简介：

2022年第44届日本造血细胞移植学会(JSTCT)年会将于2022年5月12-14日在日本横滨举行。
日本造血细胞移植学会（JSTCT）最早于1978年作为日本全国范围内一个友好讨论骨髓移植的会议，并于1980年改名为骨髓移植研究组，1996年更名为日本造血干细胞移植协会（JSHCT），2006年根据日本法律批准JSHCT成为非政府组织。JSHCT的宗旨是促进造血干细胞移植领域宣的研究，提高其结果和安全性，为患者和捐赠者的福祉做出贡献。JSHCT现拥有2,300多名成员，包括医生、护士、其他相关医疗人士、捐赠者和临床协调员、志愿者和制药公司等等。未经许可禁止复制摘录转载本站任何内容(国际医学会议网lingyuint.com)

第44回日本造血細胞移植学会総会
The 44th Annual Meeting of the Japan Society for Hematopoietic Cell Transplantation

摘要征集：

演題募集期間： 2021年8月17日（火）～ 11月1日（月）12:00まで延長しました。

The Japan Society for Hematopoietic Cell Transplantation (JSHCT) has changed its name to the Japanese Society for Transplantation and Cellular Therapy (JSTCT) since early this year, and we are pleased to announce that the first annual meeting after renaming will be held in Yokohama on May 12-14, 2022. We would like to extend a hearty welcome to all our delegates.

The Society was founded in 1978 as the Japanese Society for Bone Marrow Transplantation which has served as an annual forum for researchers and clinicians. At the 18th annual meeting held in 1995 (Tokyo, Meeting president: Professor Shigetaka Asano), the number of abstracts exceeded 200 for the first time, and this trend continued the following year when the name of society was changed to the Japan Society for Hematopoietic Cell Transplantation. The cell source, which had been mainly bone marrow cells, was being applied to peripheral blood stem cells and cord blood, and the research on the aspect of immunotherapy was also in the limelight. At that time, in the discussion on the name of the society in view of the future direction, not the "Hematopoietic Stem Cell Transplantation", but the “Hematopoietic Cell Transplantation” was adopted. It shows the foresight of the leaders at that time, late ’90s. A quarter of a century later, hematopoietic stem cell transplantation is now evolving into cell therapy using stem cells and immune cells, that change has become a reality.

On the other hand, when we look back on our history, I feel that where we are now is still in the process of evolution. Perhaps in the not-too-distant future, a new path toward overcoming intractable diseases will be opened up, and the name of our society may be changed again. By always keeping in mind that we are on the road to evolution, and with an eye on the path of hope for the next generation, There is, interestingly, a custom of attaching a theme to academic meeting in Japan, so, I have chosen the theme of this meeting as “Transplant, Cell Therapy, and Beyond”.

Even in the midst of these changes, the essence of the JSTCT2022 is to provide a forum for the exchange of information among a group of all medical professionals who aim to improve the level of treatment and care using the technologies related to transplantation and cellular therapy. Even in the era of COVID-19 pandemic starting in 2020, there are "comrades" who are devoted to clinical and research activities day and night to relieve the suffering of patients with intractable diseases. In JSTCT2022, we are planning various sessions, projects and events based on the mind of “Transplant, Cell Therapy, and Beyond”. Of course, the safety of our members is directly related to the safety of our patients, so we will be prepared to take flexible measures, such as holding the conference as a hybrid or online, depending on the situation. However, I sincerely hope that in May 2022, all of us will be able to meet in Yokohama, very beautiful city, and exchange the information of our research and clinical work and our friendship.

JSTCT2022 President
Satoshi Takahashi, MD, PhD

◆ 参会对象：医生、药剂师、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。